



Metrion Biosciences expands into new headquarters to support continued growth

- *New 12,000 sq. ft Granta Park, Cambridge (UK) premises more than doubles Metrion's laboratory space*
- *Custom designed laboratories support new GLP cardiac safety services, expanded cell biology facilities and 384-well automated electrophysiology capability*

Cambridge, UK, 22 September 2021: Metrion Biosciences Limited ("Metrion"), the specialist ion channel contract research and drug discovery company, today announced that the Company has moved to larger, custom designed laboratory and office premises at Granta Park, Cambridge, UK. The new headquarters will allow the Company to significantly expand its range of services and cell lines.

The 12,000 sq. ft (1,145 m²) facility more than doubles the Company's laboratory space and has been specifically designed to support the addition of Good Laboratory Practice (GLP) compliant cardiac safety services and expanded cell biology facilities. The new laboratories provide significant additional capacity for ongoing and future client projects, and dedicated laboratory space for the introduction of 384-well format automated electrophysiology and enhanced liquid handling. Metrion has increased its headcount by 50% over the past three years and is actively recruiting.

"Our new headquarters has been specifically designed to support Metrion's ambitious business plan for global growth, with a particular focus on the USA in 2022. Following the recent appointment of Nick Foster as Chief Commercial Officer, the additional space will also allow for further growth of Metrion's team of expert laboratory scientists," **said Dr Andrew Southan, Chief Executive of Metrion Biosciences:** *"Metrion continues to build its reputation as a leading provider of drug discovery research services for ion channel targets across multiple therapeutic areas and I look forward to working with the team during this next phase of growth for our company."*

For more information: <https://www.metrionbiosciences.com/>

-ENDS-

Notes to Editors

		
Andy Southan, Chief Executive, Metrion Biosciences	Metrion Biosciences' new HQ	Metrion Biosciences is actively recruiting to expand its team of expert laboratory scientists

For high resolution images please contact Zyme Communications

Media contact:

Katie Odgaard

Zyme Communications

E-mail: katie.odgaard@zymecommunications.com

Tel: +44 (0)7787 502 947

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please [click here](#).

About Metrion Biosciences

Metrion Biosciences is a specialist ion-channel contract research organization and drug discovery business. The Company provides customers with access to a range of high-quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences' ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Metrion Biosciences is able to provide tailored assay formats, data analysis and reporting solutions, effective project management and quality assured data packages.

For more information, please visit www.metrionbiosciences.com

LinkedIn: [@metrion-biosciences](#) | Twitter: [@metrion_biosci](#)